Hyloris PharmaceuticalsLTS:0AB6 -0.86%63 Current Ratio is 3.89 as of Dec. 2025, which is 4% above its 10-year median of 3.75. GuruFocus rates LTS:0AB6 with a GF Score™ of 63/100 and a GF Value™ of €9.52 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Hyloris Pharmaceuticals ranks worse than 50.07% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Hyloris Pharmaceuticals's current ratio for the quarter that ended in Dec. 2025 was 3.89.
Hyloris Pharmaceuticals has a current ratio of 3.89. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Hyloris Pharmaceuticals's Current Ratio or its related term are showing as below:
LTS:0AB6'
s Current Ratio Range Over the Past 10 Years
Min: 0.23 Med: 3.75 Max: 31.24
Current: 3.89
During the past 10 years, Hyloris Pharmaceuticals's highest Current Ratio was 31.24. The lowest was 0.23. And the median was 3.75.
LTS:0AB6's Current Ratio is ranked worse than 50.07% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs LTS:0AB6: 3.89
Hyloris Pharmaceuticals (LTS:0AB6) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Hyloris Pharmaceuticals Current Ratio Related Terms
Hyloris Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0AB6 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals (LTS:0AB6) has a Current Ratio of 3.89 as of Dec. 2025. This is near median its historical median of 3.75. Over the past decade, Hyloris Pharmaceuticals' Current Ratio has ranged from 0.23 to 31.24. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #707 out of 1412 companies in the Biotechnology industry, placing it in the top 50.1%.
Is Hyloris Pharmaceuticals' Current Ratio too high?
Hyloris Pharmaceuticals' current Current Ratio of 3.89 is near median its 10-year median of 3.75. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 31.24. The Biotechnology industry median Current Ratio is 3.90. Hyloris Pharmaceuticals' value of 3.89 is 0.3% below this industry median. Based on the distribution chart, Hyloris Pharmaceuticals ranks #707 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hyloris Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #707 out of 1412 companies for Current Ratio. This places Hyloris Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.90. Hyloris Pharmaceuticals' value of 3.89 is 0.3% below this benchmark. Historically, Hyloris Pharmaceuticals' own Current Ratio has ranged from 0.23 to 31.24 over the past decade. While the company's 10-year median is 3.75 vs. the industry median of 3.90, Hyloris Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyloris Pharmaceuticals's current Current Ratio of 3.89 is 0.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current Current Ratio is 3.89, which is near median its own 10-year median of 3.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.52, compared to a current price of €4.60 — trading 51.7% below its estimated fair value. The current Current Ratio is 3.89, which is near median its 10-year median of 3.75 and 0.3% below the Biotechnology industry median of 3.90. Hyloris Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Current Ratio is 3.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.60 is trading 51.7% below its estimated GF Value™ of €9.52.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LTS:0AB6:
Current Ratio: 3.89 (near median its 10-year median of 3.75)
GF Value™: €9.52 vs. price of €4.60 (51.7% below fair value)
Industry Position: 0.3% below the Biotechnology median (#707 of 1412)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
63GF Score
Get the complete analysis for LTS:0AB6
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
